NEMO-binding domain peptide inhibits proliferation of human melanoma cells

Angela Ianaro, Mariaroberta Tersigni, Giuseppe Belardo, Silvana Di Martino, Maria Napolitano, Giuseppe Palmieri, Maria Cristina Sini, Anna De Maio, Maria Neve Ombra, Giuseppina Gentilcore, Mariaelena Capone, Maria Libera Ascierto, Rocco Alfredo Satriano, Benedetta Farina, Maria Rosaria Faraone-Mennella, Paolo Antonio Ascierto, Armando Ialenti

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Melanoma is the most aggressive form of skin cancer, it originates from melanocytes and its incidence has increased in the last decade. Recent advances in the understanding of the underlying biology of the progression of melanoma have identified key signalling pathways that are important in promoting melanoma tumourigenesis, thus providing dynamic targets for therapy. One such important target identified in melanoma tumour progression is the Nuclear Factor-κB (NF-κB) pathway. In vitro studies have shown that NF-κB binding is constitutively elevated in human melanoma cultures compared to normal melanocytes. It has been found that a short cell-permeable peptide spanning the IKK-β NBD, named NBD peptide, disrupted the association of NEMO with IKKs in vitro and blocked TNFα-induced NF-κB activation in vivo. In the present study we investigated the effect of the NBD peptide on NF-κB activity and survival of A375 human melanoma cells. We found that NBD peptide is able to inhibit the proliferation of A375 cells, which present constitutively elevated NF-κB levels. Inhibition of cell proliferation by NBD peptide was associated with direct inhibition of constitutive NF-κB DNA-binding activity and induction of apoptosis by activation of caspase-3 as confirmed by the cleavage and consequently inactivation of poly (ADP ribose) polymerase (PARP-1) known as the best marker of this process.

Original languageEnglish
Pages (from-to)331-336
Number of pages6
JournalCancer Letters
Volume274
Issue number2
DOIs
Publication statusPublished - 18 Feb 2009
Externally publishedYes

Fingerprint

Melanoma
Peptides
Melanocytes
Cell Proliferation
Skin Neoplasms
Caspase 3
Protein Domains
Apoptosis
Survival
DNA
Incidence
Neoplasms
In Vitro Techniques
Therapeutics

Keywords

  • Apoptosis
  • Melanoma
  • NBD peptide
  • NF-κB

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ianaro, A., Tersigni, M., Belardo, G., Martino, S. D., Napolitano, M., Palmieri, G., ... Ialenti, A. (2009). NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Letters, 274(2), 331-336. https://doi.org/10.1016/j.canlet.2008.09.038

NEMO-binding domain peptide inhibits proliferation of human melanoma cells. / Ianaro, Angela; Tersigni, Mariaroberta; Belardo, Giuseppe; Martino, Silvana Di; Napolitano, Maria; Palmieri, Giuseppe; Sini, Maria Cristina; Maio, Anna De; Ombra, Maria Neve; Gentilcore, Giuseppina; Capone, Mariaelena; Ascierto, Maria Libera; Satriano, Rocco Alfredo; Farina, Benedetta; Faraone-Mennella, Maria Rosaria; Ascierto, Paolo Antonio; Ialenti, Armando.

In: Cancer Letters, Vol. 274, No. 2, 18.02.2009, p. 331-336.

Research output: Contribution to journalArticle

Ianaro, A, Tersigni, M, Belardo, G, Martino, SD, Napolitano, M, Palmieri, G, Sini, MC, Maio, AD, Ombra, MN, Gentilcore, G, Capone, M, Ascierto, ML, Satriano, RA, Farina, B, Faraone-Mennella, MR, Ascierto, PA & Ialenti, A 2009, 'NEMO-binding domain peptide inhibits proliferation of human melanoma cells', Cancer Letters, vol. 274, no. 2, pp. 331-336. https://doi.org/10.1016/j.canlet.2008.09.038
Ianaro A, Tersigni M, Belardo G, Martino SD, Napolitano M, Palmieri G et al. NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Letters. 2009 Feb 18;274(2):331-336. https://doi.org/10.1016/j.canlet.2008.09.038
Ianaro, Angela ; Tersigni, Mariaroberta ; Belardo, Giuseppe ; Martino, Silvana Di ; Napolitano, Maria ; Palmieri, Giuseppe ; Sini, Maria Cristina ; Maio, Anna De ; Ombra, Maria Neve ; Gentilcore, Giuseppina ; Capone, Mariaelena ; Ascierto, Maria Libera ; Satriano, Rocco Alfredo ; Farina, Benedetta ; Faraone-Mennella, Maria Rosaria ; Ascierto, Paolo Antonio ; Ialenti, Armando. / NEMO-binding domain peptide inhibits proliferation of human melanoma cells. In: Cancer Letters. 2009 ; Vol. 274, No. 2. pp. 331-336.
@article{455393ce50714694ad1f661f090f1327,
title = "NEMO-binding domain peptide inhibits proliferation of human melanoma cells",
abstract = "Melanoma is the most aggressive form of skin cancer, it originates from melanocytes and its incidence has increased in the last decade. Recent advances in the understanding of the underlying biology of the progression of melanoma have identified key signalling pathways that are important in promoting melanoma tumourigenesis, thus providing dynamic targets for therapy. One such important target identified in melanoma tumour progression is the Nuclear Factor-κB (NF-κB) pathway. In vitro studies have shown that NF-κB binding is constitutively elevated in human melanoma cultures compared to normal melanocytes. It has been found that a short cell-permeable peptide spanning the IKK-β NBD, named NBD peptide, disrupted the association of NEMO with IKKs in vitro and blocked TNFα-induced NF-κB activation in vivo. In the present study we investigated the effect of the NBD peptide on NF-κB activity and survival of A375 human melanoma cells. We found that NBD peptide is able to inhibit the proliferation of A375 cells, which present constitutively elevated NF-κB levels. Inhibition of cell proliferation by NBD peptide was associated with direct inhibition of constitutive NF-κB DNA-binding activity and induction of apoptosis by activation of caspase-3 as confirmed by the cleavage and consequently inactivation of poly (ADP ribose) polymerase (PARP-1) known as the best marker of this process.",
keywords = "Apoptosis, Melanoma, NBD peptide, NF-κB",
author = "Angela Ianaro and Mariaroberta Tersigni and Giuseppe Belardo and Martino, {Silvana Di} and Maria Napolitano and Giuseppe Palmieri and Sini, {Maria Cristina} and Maio, {Anna De} and Ombra, {Maria Neve} and Giuseppina Gentilcore and Mariaelena Capone and Ascierto, {Maria Libera} and Satriano, {Rocco Alfredo} and Benedetta Farina and Faraone-Mennella, {Maria Rosaria} and Ascierto, {Paolo Antonio} and Armando Ialenti",
year = "2009",
month = "2",
day = "18",
doi = "10.1016/j.canlet.2008.09.038",
language = "English",
volume = "274",
pages = "331--336",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - NEMO-binding domain peptide inhibits proliferation of human melanoma cells

AU - Ianaro, Angela

AU - Tersigni, Mariaroberta

AU - Belardo, Giuseppe

AU - Martino, Silvana Di

AU - Napolitano, Maria

AU - Palmieri, Giuseppe

AU - Sini, Maria Cristina

AU - Maio, Anna De

AU - Ombra, Maria Neve

AU - Gentilcore, Giuseppina

AU - Capone, Mariaelena

AU - Ascierto, Maria Libera

AU - Satriano, Rocco Alfredo

AU - Farina, Benedetta

AU - Faraone-Mennella, Maria Rosaria

AU - Ascierto, Paolo Antonio

AU - Ialenti, Armando

PY - 2009/2/18

Y1 - 2009/2/18

N2 - Melanoma is the most aggressive form of skin cancer, it originates from melanocytes and its incidence has increased in the last decade. Recent advances in the understanding of the underlying biology of the progression of melanoma have identified key signalling pathways that are important in promoting melanoma tumourigenesis, thus providing dynamic targets for therapy. One such important target identified in melanoma tumour progression is the Nuclear Factor-κB (NF-κB) pathway. In vitro studies have shown that NF-κB binding is constitutively elevated in human melanoma cultures compared to normal melanocytes. It has been found that a short cell-permeable peptide spanning the IKK-β NBD, named NBD peptide, disrupted the association of NEMO with IKKs in vitro and blocked TNFα-induced NF-κB activation in vivo. In the present study we investigated the effect of the NBD peptide on NF-κB activity and survival of A375 human melanoma cells. We found that NBD peptide is able to inhibit the proliferation of A375 cells, which present constitutively elevated NF-κB levels. Inhibition of cell proliferation by NBD peptide was associated with direct inhibition of constitutive NF-κB DNA-binding activity and induction of apoptosis by activation of caspase-3 as confirmed by the cleavage and consequently inactivation of poly (ADP ribose) polymerase (PARP-1) known as the best marker of this process.

AB - Melanoma is the most aggressive form of skin cancer, it originates from melanocytes and its incidence has increased in the last decade. Recent advances in the understanding of the underlying biology of the progression of melanoma have identified key signalling pathways that are important in promoting melanoma tumourigenesis, thus providing dynamic targets for therapy. One such important target identified in melanoma tumour progression is the Nuclear Factor-κB (NF-κB) pathway. In vitro studies have shown that NF-κB binding is constitutively elevated in human melanoma cultures compared to normal melanocytes. It has been found that a short cell-permeable peptide spanning the IKK-β NBD, named NBD peptide, disrupted the association of NEMO with IKKs in vitro and blocked TNFα-induced NF-κB activation in vivo. In the present study we investigated the effect of the NBD peptide on NF-κB activity and survival of A375 human melanoma cells. We found that NBD peptide is able to inhibit the proliferation of A375 cells, which present constitutively elevated NF-κB levels. Inhibition of cell proliferation by NBD peptide was associated with direct inhibition of constitutive NF-κB DNA-binding activity and induction of apoptosis by activation of caspase-3 as confirmed by the cleavage and consequently inactivation of poly (ADP ribose) polymerase (PARP-1) known as the best marker of this process.

KW - Apoptosis

KW - Melanoma

KW - NBD peptide

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=58149279456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149279456&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.09.038

DO - 10.1016/j.canlet.2008.09.038

M3 - Article

VL - 274

SP - 331

EP - 336

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -